Inventor · disambiguated record
Phillip Mueller
Also filed as: MUELLER PHILLIP
30 granted patents·7 pending applications·186 citations·filing 2015–2024
97Inventor score
Top patents by PatentIndex Score
37 records- 0199US11826409B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 28, 2023·6 cites·20 claims
- 0299US11786584B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·4 cites·20 claims
- 0399US11065315B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 20, 2021·12 cites·20 claims
- 0499US11058754B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·14 cites·24 claims
- 0599US10799569B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 13, 2020·14 cites·17 claims
- 0698US10532091B1Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 14, 2020·14 cites·20 claims
- 0798US10478480B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Nov 19, 2019·14 cites·20 claims
- 0898US10449238B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·18 cites·20 claims
- 0997US10500259B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersimmatics biotechnology GmbH·Filed 2017·Granted Dec 10, 2019·17 cites·20 claims
- 1097US10376568B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·14 cites·20 claims
- 1197US10155032B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Dec 18, 2018·12 cites·13 claims
- 1297US9993539B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jun 12, 2018·13 cites·13 claims
- 1396US11679147B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jun 20, 2023·2 cites·20 claims
- 1496US11672848B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jun 13, 2023·2 cites·20 claims
- 1596US11576956B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 14, 2023·2 cites·20 claims
- 1696US9908920B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersimmatics biotechnology GmbH·Filed 2016·Granted Mar 6, 2018·15 cites·22 claims
- 1794US10064926B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Sep 4, 2018·12 cites·4 claims
- 1891US11786583B2Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·1 cites·20 claims
- 1991US2024016908A1Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2091US2024408166A1Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2185US12180259B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 31, 2024·0 cites·19 claims
- 2285US12144852B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Nov 19, 2024·0 cites·19 claims
- 2385US12102670B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 1, 2024·0 cites·19 claims
- 2485US12097249B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 24, 2024·0 cites·20 claims
- 2585US12076381B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 2685US11779638B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 10, 2023·0 cites·20 claims
- 2785US2022152175A1Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2884US11559573B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
- 2982US12121572B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 22, 2024·0 cites·19 claims
- 3082US12097248B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 24, 2024·0 cites·19 claims
- 3182US12076380B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 3, 2024·0 cites·19 claims
- 3282US12070491B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 27, 2024·0 cites·19 claims
- 3375US2020405831A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 3473US2020376103A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 3570US11406693B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 9, 2022·0 cites·12 claims
- 3666US2018207252A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Application pending·0 cites
- 3761US2017080070A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Phillip Mueller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →